| __timestamp | Amneal Pharmaceuticals, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 5114000 |
| Thursday, January 1, 2015 | 109679000 | 13403000 |
| Friday, January 1, 2016 | 118757000 | 31056000 |
| Sunday, January 1, 2017 | 109046000 | 35845000 |
| Monday, January 1, 2018 | 230435000 | 48294000 |
| Tuesday, January 1, 2019 | 289598000 | 63488000 |
| Wednesday, January 1, 2020 | 326727000 | 88208000 |
| Friday, January 1, 2021 | 365504000 | 102802000 |
| Saturday, January 1, 2022 | 399700000 | 102464000 |
| Sunday, January 1, 2023 | 429675000 | 76162000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Amneal Pharmaceuticals, Inc. and CRISPR Therapeutics AG, two prominent players in the industry, have shown contrasting approaches over the past decade. From 2014 to 2023, Amneal's SG&A expenses surged by over 400%, peaking at approximately $430 million in 2023. In contrast, CRISPR Therapeutics AG maintained a more conservative growth, with expenses increasing by about 1,400% but still only reaching around $76 million in 2023. This stark difference highlights Amneal's aggressive expansion strategy, while CRISPR focuses on lean operations. As the biotech landscape evolves, these strategies will play a pivotal role in shaping their financial futures. Investors and industry analysts should closely monitor these trends to gauge the companies' operational efficiencies and strategic directions.
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Novartis AG or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Sanofi vs Amneal Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Alkermes plc and CRISPR Therapeutics AG: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amneal Pharmaceuticals, Inc. and MiMedx Group, Inc.
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and BioCryst Pharmaceuticals, Inc.